JP6087911B2 - 有機化合物 - Google Patents
有機化合物 Download PDFInfo
- Publication number
- JP6087911B2 JP6087911B2 JP2014517231A JP2014517231A JP6087911B2 JP 6087911 B2 JP6087911 B2 JP 6087911B2 JP 2014517231 A JP2014517231 A JP 2014517231A JP 2014517231 A JP2014517231 A JP 2014517231A JP 6087911 B2 JP6087911 B2 JP 6087911B2
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- compound
- pharmaceutical composition
- disease
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2011/041866 | 2011-06-24 | ||
| PCT/US2011/041866 WO2012177263A1 (en) | 2011-06-24 | 2011-06-24 | Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists |
| US201161501207P | 2011-06-25 | 2011-06-25 | |
| US61/501,207 | 2011-06-25 | ||
| PCT/US2012/043880 WO2012178112A1 (en) | 2011-06-24 | 2012-06-22 | Organic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517078A JP2014517078A (ja) | 2014-07-17 |
| JP2014517078A5 JP2014517078A5 (enExample) | 2015-10-01 |
| JP6087911B2 true JP6087911B2 (ja) | 2017-03-01 |
Family
ID=47422974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517231A Active JP6087911B2 (ja) | 2011-06-24 | 2012-06-22 | 有機化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9469625B2 (enExample) |
| EP (1) | EP2723173B1 (enExample) |
| JP (1) | JP6087911B2 (enExample) |
| KR (1) | KR20140036305A (enExample) |
| CN (1) | CN103717069B (enExample) |
| AU (2) | AU2012272680A1 (enExample) |
| BR (1) | BR112013033306A2 (enExample) |
| CA (2) | CA2840047A1 (enExample) |
| ES (1) | ES2627338T3 (enExample) |
| IL (1) | IL230036A (enExample) |
| MX (1) | MX342322B (enExample) |
| RU (1) | RU2610094C2 (enExample) |
| WO (3) | WO2012177263A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012177263A1 (en) * | 2011-06-24 | 2012-12-27 | Intra-Cellular Therapies, Inc. | Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists |
| US11491150B2 (en) | 2017-05-22 | 2022-11-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019152680A1 (en) * | 2018-01-31 | 2019-08-08 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating cancer using chrna6 inhibitors |
| WO2020146384A1 (en) | 2019-01-07 | 2020-07-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2021008565A1 (zh) * | 2019-07-16 | 2021-01-21 | 清华大学 | 乙酰胆碱通路调节剂在治疗癌症中的用途 |
| EP4238970A1 (en) * | 2022-03-03 | 2023-09-06 | InterAx Biotech AG | Modulators of ackr3 and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| PE20021019A1 (es) * | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| ES2338539T3 (es) * | 2001-11-01 | 2010-05-10 | Icagen, Inc. | Pirazolamidas para uso en el tratamiento del dolor. |
| BR0315056A (pt) | 2002-11-01 | 2005-08-16 | Pharmacia & Upjohn Co Llc | Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central |
| MXPA05007689A (es) * | 2003-01-22 | 2005-09-30 | Pharmacia & Upjohn Co Llc | Tratamiento de enfermedades con agonistas completos del receptor alfa-7 de nach. |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| JP2006525355A (ja) * | 2003-05-01 | 2006-11-09 | アボット・ラボラトリーズ | ナトリウムチャンネルモジュレーターとしてのピラゾール−アミドおよびスルホンアミド |
| US20040220170A1 (en) * | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| EP1638944A1 (en) * | 2003-06-12 | 2006-03-29 | Eli Lilly And Company | Tachykinin receptor antagonists |
| WO2009112459A1 (en) | 2008-03-11 | 2009-09-17 | Neurosearch A/S | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| US20100179186A1 (en) | 2008-10-10 | 2010-07-15 | University Of Kentucky Research Foundation | USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS |
| WO2012177263A1 (en) | 2011-06-24 | 2012-12-27 | Intra-Cellular Therapies, Inc. | Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists |
-
2011
- 2011-06-24 WO PCT/US2011/041866 patent/WO2012177263A1/en not_active Ceased
-
2012
- 2012-06-22 CA CA2840047A patent/CA2840047A1/en not_active Abandoned
- 2012-06-22 US US14/128,378 patent/US9469625B2/en active Active
- 2012-06-22 AU AU2012272680A patent/AU2012272680A1/en not_active Abandoned
- 2012-06-22 ES ES12802484.1T patent/ES2627338T3/es active Active
- 2012-06-22 WO PCT/US2012/043813 patent/WO2012178057A1/en not_active Ceased
- 2012-06-22 KR KR1020147000636A patent/KR20140036305A/ko not_active Withdrawn
- 2012-06-22 CA CA2840373A patent/CA2840373A1/en not_active Abandoned
- 2012-06-22 JP JP2014517231A patent/JP6087911B2/ja active Active
- 2012-06-22 EP EP12802484.1A patent/EP2723173B1/en active Active
- 2012-06-22 RU RU2014102191A patent/RU2610094C2/ru not_active IP Right Cessation
- 2012-06-22 US US14/127,699 patent/US9108949B2/en active Active
- 2012-06-22 BR BR112013033306A patent/BR112013033306A2/pt not_active IP Right Cessation
- 2012-06-22 MX MX2014000255A patent/MX342322B/es active IP Right Grant
- 2012-06-22 WO PCT/US2012/043880 patent/WO2012178112A1/en not_active Ceased
- 2012-06-22 AU AU2012272646A patent/AU2012272646B2/en not_active Ceased
- 2012-06-22 CN CN201280035785.5A patent/CN103717069B/zh active Active
-
2013
- 2013-12-19 IL IL230036A patent/IL230036A/en active IP Right Grant
-
2015
- 2015-06-17 US US14/742,570 patent/US9452160B2/en active Active
-
2016
- 2016-01-11 US US14/993,048 patent/US9708294B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160237061A1 (en) | 2016-08-18 |
| WO2012177263A1 (en) | 2012-12-27 |
| WO2012178112A1 (en) | 2012-12-27 |
| AU2012272646A1 (en) | 2014-02-20 |
| US9708294B2 (en) | 2017-07-18 |
| MX342322B (es) | 2016-09-23 |
| MX2014000255A (es) | 2014-08-21 |
| WO2012178057A1 (en) | 2012-12-27 |
| US9469625B2 (en) | 2016-10-18 |
| IL230036A (en) | 2016-10-31 |
| US9452160B2 (en) | 2016-09-27 |
| AU2012272646B2 (en) | 2016-09-08 |
| CA2840047A1 (en) | 2012-12-27 |
| EP2723173B1 (en) | 2017-04-19 |
| US20140205596A1 (en) | 2014-07-24 |
| US20140205595A1 (en) | 2014-07-24 |
| CN103717069A (zh) | 2014-04-09 |
| KR20140036305A (ko) | 2014-03-25 |
| CN103717069B (zh) | 2018-06-05 |
| US9108949B2 (en) | 2015-08-18 |
| BR112013033306A2 (pt) | 2016-08-16 |
| RU2610094C2 (ru) | 2017-02-07 |
| JP2014517078A (ja) | 2014-07-17 |
| US20160008343A1 (en) | 2016-01-14 |
| EP2723173A1 (en) | 2014-04-30 |
| AU2012272680A1 (en) | 2014-02-20 |
| CA2840373A1 (en) | 2012-12-27 |
| ES2627338T3 (es) | 2017-07-27 |
| EP2723173A4 (en) | 2015-02-18 |
| RU2014102191A (ru) | 2015-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6630374B2 (ja) | τリン酸化を阻害する方法 | |
| US9708294B2 (en) | Organic compounds | |
| Zishiri et al. | Quinoline antimalarials containing a dibemethin group are active against chloroquinone-resistant Plasmodium falciparum and inhibit chloroquine transport via the P. falciparum chloroquine-resistance transporter (PfCRT) | |
| KR20110011669A (ko) | Rho 키나제를 억제하고 학습 및 기억력을 개선하기 위한 화합물 | |
| JP2010540439A (ja) | 神経保護性の及び認知を向上させる性質を備えた水素化されたピリド[4,3−b]インドール類のフッ素を含有する誘導体、調製するための工程、並びに使用 | |
| CA2895162C (en) | Methods and compositions for inhibiting cnksr1 | |
| CN107383002B (zh) | 一类含氟三氮唑并吡啶类化合物及其制备方法、药物组合物和用途 | |
| EP3091982B1 (en) | Organic compounds | |
| Knaab et al. | 3-Hydroxy-propanamidines, a new class of orally active antimalarials targeting Plasmodium falciparum | |
| KR20200143454A (ko) | 골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제 | |
| WO2024064778A2 (en) | Small molecule inhibitors of neutrophil exocytosis and inflammation | |
| WO2018187509A1 (en) | Heterocyclic compounds as chemokine receptor modulators | |
| EP3881840A1 (en) | Sortilin antagonists for use inthe treatment of diabetic retinopathy | |
| JP2008517065A (ja) | Brca2−rad51相互作用の破壊のための組成物及び方法 | |
| TW201821076A (zh) | Bmp增強劑 | |
| WO2025101571A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders | |
| WO2025072544A1 (en) | Sulfonamino indazole compounds as inhibitors of parg | |
| WO2025101588A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders | |
| WO2025101575A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders | |
| CA3064017A1 (en) | 6-5 fused rings as c5a inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20141215 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150619 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150811 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160204 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160216 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160512 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160715 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160816 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170202 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6087911 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |